On March 5, 2014 examiner, Wendy Spickerman received information, which the Tinnitus Clinical Trial Site released on March 3, 2014.
This information provided by an anonymous source stated, “Research Update for those in the US: Micro Transponder has announced that its US clinical trial is now open for enrolment. Three sites are enrolling Buffalo, New York, Dallas, Texas, and Iowa City, Iowa. There will be additional trials for those outside these trial sites or outside of the US; extending to Europe eventually.”
At the present time, Micro Transponder has not put out a press release on their website with this information. We have tried to contact them for verification reasons but no response has come back. However, the information has gone viral even before a press release.
On March 6, 2014, we received an e-mail stating, "A press release would be coming out within the next 4 hours from NIH." That information has now been received and we here at Examiner.com are happy to inform you.
Micro Transponder has now released this information on their site. “3/6/14 NIH Press Release,
NIH Announces the Opening of Recruitment for Micro Transponder’s Tinnitus Clinical Trial.”
This trial is supported by the National Institute on Deafness and Other Communication Disorders, known as (NIDCD). If all goes well it may mark the change in how Tinnitus is treated.
“Tinnitus affects nearly 24 million adult Americans. It is also the number one service-connected disability for returning veterans from Iraq and Afghanistan. The kind of nervous system stimuli used for this study has already shown too safely and effectively help people with other conditions such as epilepsy and depression,” said James F. Battey, Jr., M.D., PhD. Director of NIDCD.
The National Institute of Health stated, “For this new study, two groups of adults who have had moderate-to-severe tinnitus for at least one year will participate in daily 2.5 hour sessions of VNS and audio tone therapy over six weeks. One group will get the VNS and tone test treatment immediately; the other will get a combination of VNS and tones that are not expected to have a therapeutic benefit. After six weeks, both groups will receive active test treatment.
Outcomes will be measured throughout the yearlong trial using the Tinnitus Functional Index and the Tinnitus Handicap Questionnaire, two questionnaires that allow patients to report on the extent of their tinnitus. They will also be tested periodically to determine changes in minimum masking levels for the tinnitus – the decibel level of sound required to eliminate awareness of the tinnitus.”
For more information about tinnitus, go to the National Institute of Health.